The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Updates: Citalopram hydrobromide, Statins, and More

Drug Updates: Citalopram hydrobromide, Statins, and More

May 8, 2012 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Drug Safety

Citalopram hydrobromide, the racemic mixture of R- and S-isomers, is having its warning clarified based on an ongoing data evaluation from the U.S. Food and Drug Administration (FDA).1 The original updated safety information was reported in August 2011 and warned of dysrhythmias related to high doses of citalopram hydrobromide. Additional, new label changes are related to the potential for QT interval prolongation and Torsade de Pointes, as well as new drug dosage and usage recommendations. These new recommendations recognize that citalopram should be avoided in people with certain conditions—such as those with congenital long QT syndrome, bradycardia, hypokalemia, or hypomagnesemia; those who have had a recent acute myocardial infarction; or those with uncompensated heart failure—because of the risk of QT prolongation. The new label recommendation for patients with congenital long QT syndrome has been changed from “contraindicated” to “not recommended.”

You Might Also Like
  • Rheumatology Drug Updates: Apremilast, Golimumab, and More
  • Drug Updates
  • Drug Updates: Lorcaserin, Acetaminophen, and More
Explore This Issue
May 2012
Also By This Author
  • Guselkumab Promising in Patients with PsA

Citalopram use is also not recommended in patients who are taking other potential QT-interval prolonging drugs. Additionally, the maximum recommended daily citalopram dose is 20 mg for patients with hepatic impairment, those who are older than 60 years of age, those who are CYP 2C19 poor metabolizers, or those who are taking concomitant cimetidine or other CYP2C19 inhibitors. This is because these can lead to increased citalopram blood levels leading to an increased risk of QT-interval prolongation and Torsade de Pointes. Electrocardiogram (ECG) and/or electrolyte monitoring should be performed if citalopram is going to be used in these patients. Other patients may also require ECG monitoring. Citalopram should be discontinued in patients who are found to have persistent QTc measurements greater than 500 milliseconds.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Statins, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, recently underwent important label and safety changes.2 Due to the unpredictability of serious hepatic injury in statin users, and the fact that monitoring more frequently does not seem to prevent hepatic injury, the labeling of all statins have been updated to reflect a change in this monitoring. This comes from an extensive review of statin data, carried out by the FDA. The review determined that all available statins are associated with a very low risk of serious hepatic injury, which is not averted by routine serum alanine aminotransferase monitoring. It is now recommended that physicians monitor liver enzymes before starting statins and as clinically indicated thereafter.

In addition, the effect of statins on cognition was evaluated by the FDA by reviewing its Adverse Event Reporting System (AERS) database as well as published medical literature and randomized clinical trials. The postmarketing adverse-event reports most commonly describe cognitive impairment in people older than age 50, whose memory impairment (e.g., loss or impairment) abated upon discontinue of the statin. No associations were noted between the impairment and any particular statin or statin dose, patient age, or other associated medication use. Occurrence was very variable, and could occur from one day following commencement of the statin through years of use. It was not connected to dementia. Information derived from observational studies and clinical studies did not indicate that cognitive changes are common or lead to progressive cognitive decline.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Drug Updates Tagged With: Approvals, Biologics, drug, JAK inhibitors, janus kinase, Pipeline, Rheumatoid arthritis, Safety, StatinIssue: May 2012

You Might Also Like:
  • Rheumatology Drug Updates: Apremilast, Golimumab, and More
  • Drug Updates
  • Drug Updates: Lorcaserin, Acetaminophen, and More
  • Rheumatology Drug Updates

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)